Harold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD

Similar documents
Arkansas Prescription Monitoring Program

Wisconsin Statewide Substance Abuse Prevention Training Wisconsin Dells June 12, 2015

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

Oregon Prescription Drug Monitoring Program

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Arkansas Department of Health

Oregon s PDMP: An epidemiological assist tool

Interstate Variation in Prescribing of Opioid Pain Relievers and Benzodiazepines Karin A. Mack, PhD Associate Director for Science

Controlled Substances Board

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities

Nebraska: What s Going On with the PDMP and HIE

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update

North Dakota Board of Pharmacy

New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

C U S T O M E R D R I V E N. B U S I N E S S M I N D E D.

Opioid Abuse and Prescribing. Dr. Mitchell Mutter Director of Special Projects

Reducing Opioid Deaths: Arizona s Emergency Declaration & Response

using analytics to identify and strategically manage patient opioid abuse

ANNUAL REPORT

The Wisconsin Prescription Drug Monitoring Program

COLORADO PRESCRIPTION DRUG MONITORING PROGRAM

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

D. Todd Bess, PharmD 1

U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs

Opioids drive continued increase in drug overdose deaths

Our Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System

VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC

Interventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference?

A National Perspective on the Abuse and Diversion of Prescription Drugs

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

Opioid Deaths in South Carolina. Daniela Nitcheva, PhD Division of Biostatistics Bureau of Public Health Statistics

& CONSUMES 80% 5% OF THE WORLD S POPULATION 5/19/2017. New Naloxone Regulations & the Importance of Using PRESCRIPTION DRUG ABUSE EPIDEMIC

VIRGINIA DEPARTMENT OF HEALTH OFFICE OF THE CHIEF MEDICAL EXAMINER

ACCG Mental Health Summit

Arkansas Prescription Monitoring Program

PDMP Tools to Identify Red Flag Situations

Data Integration and Analysis for Improved Drug Overdose Surveillance in Kentucky

4/12/2018. Opioid Addiction and Prescribing. Disclosure Statement of Financial Interest

SCRIPTS. South Carolina Reporting & Identification Prescription Tracking System

Protecting Children s Safety: How Prescription Drug Monitoring Programs Can Assist An Update Presenter: John L. Eadie Moderator: Cindy Rodgers

Addressing the Opioid Epidemic in Tennessee

Harold Rogers Update Melissa McPheeters, PhD, MPH

UT HEALTH S RESPONSE TO

Arkansas Prescription Monitoring Program

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

Kentucky All Schedule Prescription Electronic Reporting (KASPER)

Proactive Analysis of Specialized Databases

Touchpoints Prior to Opioid Overdose Death

Maine PMP Update. Daniel Eccher, MPH MPA Convention May 20, 2011

Prescription Monitoring Program Center for Excellence, Brandeis University. April 10-12, 2012 Walt Disney World Swan Resort

Mark W. Caverly, Chief Liaison and Policy Section

PRESCRIPTION DRUG MONITORING PROGRAM

New Guidelines for Prescribing Opioids

Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT

The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017

COUNTY OF SAN DIEGO. Opioid Update

An Evaluation of the DoD Transdermal Fentanyl Pharmacy Edit. LTC Stacia Spridgen, MSC, USA Director, DoD Pharmacoeconomic Center

SAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM

PDMP prescriber use mandates: characteristics, current status, and outcomes in selected states

Opioid Overdose Education and Naloxone Distribution

The Latest Prescription Trends for Controlled Prescription Drugs

PRESCRIPTION DRUG MONITORING PROGRAM ST. CHARLES COUNTY Q1 2018

NJPMP & Safer Prescribing

Using PDMP Data to Guide Interventions with Possible At-Risk Prescribers

Washington State PMP Data Mapping Project

Opioid Overdose in Oregon Report to the Legislature

Prescription Monitoring Program

Report to the Legislature: Impact of the Minnesota Prescription Monitoring Program on Doctor Shopping

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

Shannon Whitman Program Administrator Advancing Use of the MN PMP

Greenbrier County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Report to the Legislature: Recommendations on Required Use and Other Uses of the MN Prescription Monitoring Program Database

Preparing for Electronic Prescribing of Controlled Substances (EPCS) in New York

Dr. Smith. Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force

CDC s Approach to Addressing the Opioid Overdose Epidemic

2018 Annual Meeting & Educational Conference Opioids In Workers Compensation: Research From WCRI

Confronting the Opioid Epidemic

Comprehensive Opioid Abuse Program (COAP) Category 6 Grantees Call

Presentation Objectives

2017 NASCSA Conference

Prescription Monitoring Programs: An Update on Interstate Data Sharing

Carisoprodolol Quantity Limit Policy Impact Analysis

Poisoning Death Review Report. Montgomery County, 2017

Status of Opioid Treatment Efforts

Federal and State Controlled Substance Laws and Guidelines. Good Medicine for Prescribers and Patients

WHAT YOU NEED TO KNOW TO ABOUT AB 474

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

Drug Overdose in New Mexico

Pennsylvania Prescription Drug Monitoring Program Trends,

CONGRESSIONAL BRIEFING. PRESCRIPTION DRUG MONITORING PROGRAMS (PDMPs): CRITICAL DECISION SUPPORT TOOLS TO RESPOND TO THE OPIOID CRISIS

Managing Risks Associated with Doctor Shopping and Other Drug-Seeking Behaviors

An Update on Kentucky All Schedule Prescription Electronic Reporting (KASPER)

STATE PRESCRIPTION DRUG MONITORING PROGRAMS (PMPS): A NATIONAL PERSPECTIVE

Barbour County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report Barbour County

Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices

A Different Kind of Drug War. CINDY SANDERS Posted: Thursday, April 5, :07 pm. Providers Focus on Prescription Drug Addiction, Abuse

TN Opioid Program. Erica Schlesinger, Pharm.D

Mingo County. West Virginia Board of Pharmacy Prescription Opioid Problematic Prescribing Indicators County Report

Prescription Opioid Overdose in Oregon: A public health perspective

Addressing Prescription Drug Abuse. Allan Coukell Senior Director, Drugs and Medical Devices The Pew Charitable Trust

Transcription:

Harold Rogers Prescription Drug Monitoring Program Regional Meeting-Charleston, SC April 29, 2014 Andrew Holt, PharmD

National Epidemic Highlighted numerous studies/media reports State Epidemic Highlighted several state-level studies/statistics Governor forms Public Safety Subcabinet Addresses many areas of public safety, including prescription drug abuse Overdose Deaths Overdoses NAS

Source: Tennessee Department of Health internal files, Baumblatt, et al

Source: Tennessee Department of Health internal files, Baumblatt, et al

Source: Tennessee Department of Health internal files, Baumblatt et al

Source: Department of Health internal files, Baumblatt et al

Source: Tennessee Department of Health internal files, Baumblatt et al

Number of Overdose Deaths Overdose Deaths 1200 1000 800 600 400 342 391 422 484 660 753 868 963 972 924 929 1059 1062 1094 200 0 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 Year International Classification of Diseases (ICD) version 10 cause of death codes X40-X44, X60-X64, X85, and Y10-Y14. Source: Tennessee Department of Health, Division of Policy, Planning and Assessment, Office of Health Statistics.

Administration bill introduced as a work product of the Governor s Public Safety Subcabinet Amended during the legislative process Passed by unanimous vote of both chambers on May 1, 2012 Signed by Governor Haslam on May 10, 2012.

Required registration as of January 1, 2013 Required checking of PMP as of April 1, 2013 in most cases involving the prescribing of an opioid or benzodiazepine Enabled interstate data sharing Established delegate accounts- extenders Increased administrative staffing

Automated Registration Web service established between vendor and: State professional licensing database State driver s license database Check against DEA database at vendor level Any non-matches are sent to PMP administrator for manual approval Established delegate accounts-extenders

Added capacity at vendor Hardware: Increased number of CPUs, Virtual Servers, Ram to handle 30 million transactions per year with a response time of 10.4 seconds or less in peak time; or 1,000 concurrent transactions per second with maximum query response time of 10.4 seconds per transaction during peak hours Personnel PMIX Interface Training database Use for demonstration purposes

Automated username retrieval Multiple practice locations per user Enhanced linking of extenders to supervisors Extender runs report on supervisor behalf Supervisor can run report on extenders Prescribing history and request history

Sent via email to all prescribers registered in the PDMP Over 900 responses Purpose was to seek feedback about the PDMP and the Prescription Safety Act

71% changed a treatment plan after viewing a PDMP report 73% are more likely to discuss substance abuse issues or concerns with a patient 57% are more likely to refer a patient for substance abuse treatment 79% feel that the PDMP is useful for decreasing doctor shopping

Jan 2012 Feb 2012 Mar 2012 Apr 2012 May 2012 Jun 2012 Jul 2012 Aug 2012 Sep 2012 Oct 2012 Nov 2012 Dec 2012 Jan 2013 Feb 2013 Mar 2013 Apr 2013 May 2013 Jun 2013 Jul 2013 Aug 2013 Sep 2013 Oct 2013 Nov 2013 Dec 2013 Jan 2014 Feb 2014 Mar 2014 Requests per Month Number of Registrants Number of Requests/Month Number of Registrants at Month End 600000 40000 500000 35000 30000 400000 25000 300000 20000 200000 15000 10000 100000 5000 0 0 Source: Tennessee Department of Health internal files

1,200,000 1,000,000 800,000 600,000 400,000 CSMD Searches by Delegates CSMD Searches by Prescibers 200,000 0 Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Q2 2013 Q3 2013 Q4 2013 Source: Tennessee Department of Health internal files

Table 6. Number of Patient Requests from CSMD, 2010-2013 Year Healthcare Providers Law Enforcement 2010 1,200,435 N/A 2011 1,486,932 551 2012 1,861,485 2,565 2013 4,497,866 1,938 Source: CSMD Annual Report to the 108th General Assembly, 2014

Table 2. Number of Controlled Substances Prescriptions (by class) Reported to CSMD, 2010-2013* Year Opioids % Change Benzodiazepines % Change Other % Change 2010 8,150,946-3,951,144-4,423,662-2011 9,018,139 10.6 4,152,587 5.1 5,001,445 13.1 2012 9,265,450 2.7 4,061,418-2.2 5,125,142 2.5 2013 9,227,456-0.4 3,913,356-3.6 5,433,347 6 * Classes of controlled substances were defined based on CDC guidance document. Source: CSMD Annual Report to the 108th General Assembly, 2014

Table 3. Comparison of the 10 most frequently prescribed products in 2012 and 2013 in CSMD Rank 2013 2012 1 Hydrocodone products Hydrocodone products 2 Alprazolam Alprazolam 3 Oxycodone products Oxycodone products 4 Zolpidem Zolpidem 5 Tramadol Tramadol 6 Clonazepam Clonazepam 7 Lorazepam Lorazepam 8 Diazepam Diazepam 9 Morphine products Buprenorphine products 10 Buprenorphine products Morphine products Source: CSMD Annual Report to the 108th General Assembly, 2014

Source: CSMD Annual Report to the 108th General Assembly, 2014

C-II Controlled Substances Year Rx s Per Capita (TN Rank lower is better) 2008 TN: 0.53/person (4) US: 0.39/person 2012 TN: 0.64/person (2) US: 0.41/person 2013 TN: 0.68/person (2) US: 0.42/person Percent Change in Filled Rx s from Previous Year (TN Rank lower is better) N/A TN: 7.4% (23) US: 7.0% TN: 0.3% (31) US: 0.7% 24 Source: IMS Health, Inc.

MME in Billions 10.0 9.8 9.6 9.4 9.2 9.0 8.8 8.6 8.4 8.2 2010 2011 2012 2013 MME Reported by Newly Reporting Dispensers MME Reported by All Other Sources 25 Source: Tennessee Department of Health Internal Files, February 2014

Source: CSMD Annual Report to the 108th General Assembly, 2014

Patient Requests (in Millions) High Utilization Patients 5.0 10000 4.5 4.0 3.5 9000 8000 7000 Number of Searches Made by Prescibers, Dispensers, and Delegates 3.0 6000 2.5 2.0 1.5 1.0 0.5 5000 4000 3000 2000 1000 High Utilization Patients: Patients filled 5 or more prescriptions with different DEA Prescribers at 5 or more different DEA dispensers within 90 days. 0.0 2010 2011 2012 2013 0 27 Source: Tennessee Department of Health Internal Files, February 2014

Dr. David Udoko Keshia Evans James Graddey David Jones Debora Sanford (Project Manager) Dr. Zhi Chen (Epidemiologist)

Andrew Holt, PharmD Director Tennessee Controlled Substance Monitoring Database 665 Mainstream Dr. Nashville, TN 37243 615-253-1300 Andrew.holt@tn.gov